COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Safety Study of the Drug MM-151 in Patients With Advanced Solid Tumors Resisting Ordinary Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01520389
Recruitment Status : Completed
First Posted : January 30, 2012
Last Update Posted : March 21, 2018
Information provided by (Responsible Party):
Merrimack Pharmaceuticals

Brief Summary:
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design, evaluating MM-151 at varying dose levels and frequencies, and subsequently in combination with irinotecan.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Colorectal Cancer Squamous Cell Head and Neck Cancer Non Small Cell Lung Cancer Triple Negative Breast Cancer Drug: MM-151 Drug: MM-151 + irinotecan Phase 1

Detailed Description:
This study is a Phase 1 and pharmacologic open-labeled dose-escalation trial using a "3+3" design exploring weekly, bi-weekly, and tri-weekly dosing schedules. Successive MM-151 monotherapy cohorts of three or more patients will be treated at escalating doses until a maximum tolerated dose is identified, and subsequently in combination with irinotecan. The study consists of three parts as follows: MM-151 monotherapy dose escalation (Part 1); MM-151 monotherapy expansion cohort in cetuximab-refractory colorectal cancer (Part 2); MM-151 + irinotecan dose escalation (Part 3). It is expected that approximately 4 study sites will participate.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 112 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 and Pharmacologic Study of MM-151 in Patients With Refractory Advanced Solid Tumors
Study Start Date : January 2012
Actual Primary Completion Date : December 2015
Actual Study Completion Date : January 2016

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: MM-151 Dose Escalation
MM-151 Dose escalation frequency - once weekly, once every two weeks, once every three weeks
Drug: MM-151

Experimental: MM-151 Expansion in KRAS wild type colorectal cancer
MM-151 given weekly
Drug: MM-151

Experimental: MM-151 + irinotecan
MM-151 given weekly, irinotecan 180 mg/m2 given once every two weeks
Drug: MM-151 + irinotecan
MM-151 + irinotecan
Other Name: camptosar

Primary Outcome Measures :
  1. Phase II dose of MM-151 alone and in combination with irinotecan based either on the maximum tolerated dose (MTD) or maximum dose of 18 mg/kg in patients with advanced solid malignancies. [ Time Frame: Two years ]

Secondary Outcome Measures :
  1. Number of dose limiting toxicities (DLTs) within a cohort [ Time Frame: 2 years ]
  2. Adverse event profile of MM-151 alone and in combination with irinotecan [ Time Frame: 2 years ]
  3. Objective response to MM-151 alone and in combination with irinotecan based on RECIST [ Time Frame: 2 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must have histologically or cytologically confirmed advanced malignant solid tumor that has recurred or progressed following standard therapy, or that has not responded to standard therapy, or for which there is no standard therapy, or who are not candidates for standard therapy
  • Patients must be > 18 years of age
  • Patients of their legal representatives must be able to understand and sign an informed consent form
  • Patients must have evaluable or measurable tumor(s)
  • Patients must be recovered from the effects of any prior surgery, radiotherapy or other antineoplastic therapy. Up to CTCAE Grade 1 is acceptable for patients with known peripheral neuropathy
  • Women of childbearing potential as well as fertile men and their partners must agree to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-151 (an effective form of contraception is an oral contraceptive or a double barrier method)

Exclusion Criteria:

  • Patients for whom potentially curative antineoplastic therapy is available
  • Patients who are pregnant or lactating
  • Patients with an active infection or with an unexplained fever > 38.5°C during screening visits or on the first scheduled day of dosing. (At the discretion of the investigator, patients with tumor fever may be enrolled.)
  • Patients with untreated and/or symptomatic CNS malignancies (primary or metastatic); patients with CNS metastases who have undergone surgery or radiotherapy, whose disease is stable, and who have been on a stable dose of corticosteroids for at least 2 weeks prior to the first scheduled day of dosing will be eligible for the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01520389

Layout table for location information
United States, Colorado
University of Colorado Denver
Aurora, Colorado, United States, 80045
United States, Indiana
Horizon Oncology Research, Inc.
Lafayette, Indiana, United States, 47905
United States, New York
Roswell Park Cancer Institute
Buffalo, New York, United States, 14263
United States, Texas
South Texas Accelerated Research Therapeutics, LLC (START)
San Antonio, Texas, United States, 78229
Sponsors and Collaborators
Merrimack Pharmaceuticals
Layout table for additonal information
Responsible Party: Merrimack Pharmaceuticals Identifier: NCT01520389    
Other Study ID Numbers: MM-151-01-01-01
First Posted: January 30, 2012    Key Record Dates
Last Update Posted: March 21, 2018
Last Verified: March 2018
Keywords provided by Merrimack Pharmaceuticals:
solid tumors
Phase I
EGF receptor (ErbB1)
Additional relevant MeSH terms:
Layout table for MeSH terms
Triple Negative Breast Neoplasms
Neoplasms by Site
Breast Neoplasms
Breast Diseases
Skin Diseases
Antibodies, Monoclonal
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Immunologic Factors
Physiological Effects of Drugs